According to Aerpio Pharmaceuticals (ARPO) website, they are a bio pharmaceutical company focused on advancing first-in-class treatments for ocular diseases.
Personally, I think the description is far too narrow and base my opinion on both the company's recent strong secondary readouts from a "failed" drug trial and its partnership with Gossamer Bio (GOSS).
While it was the initial one-day 71% haircut on March 18, 2019, that first put this company on my radar (ultimately bottoming out at $.88 on March 29), it was the value proposition the drop created that had me buying